Open AccessThe risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings
Author(s) -
Magnhild SandbergWollheim,
Gabrielle Kornmann,
Dorina Bischof,
Margaretha Stam Moraga,
Bryan T. Hennessy,
Enrica Alteri
Publication year - 2011
Publication title -
multiple sclerosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.729
H-Index - 131
eISSN - 1477-0970
pISSN - 1352-4585
DOI - 10.1177/1352458511403642
Subject(s) - medicine , malignancy , clinical trial , incidence (geometry) , confidence interval , population , placebo , odds ratio , interferon beta 1a , multiple sclerosis , oncology , interferon beta , pathology , immunology , alternative medicine , physics , environmental health , optics
Risks that are potentially associated with long-term therapies should be assessed.